Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna
Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) INGELHEIM, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Boehringer Ingelheim and Dicerna Pharmaceuticals...